Pfizer Inc. (NYSE: PFE) revealed that it received European Commission approval for its XALKORI (crizotinib) for the treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC). The American regulator has approved it in March for patients with metastatic NSCLC with ROS1-positive.

Pfizer said that as a result of the EU approval, its XALKORI has become the only biomarker therapy approved for patients in the United States and the European Union. The EU decision was based on the Committee for Medicinal Products for Human Use (CHMP) supported by Phase one trial.

Related Link: In Wake Of Medivation Deal, Argus Thinks Pfizer's Existing Business Is Underrated

The drug maker's Regional President for International Developed Markets, Andreas Penk, said, "We now know that NSCLC is not a single disease, but includes a number of molecularly defined tumors with different clinical characteristics and treatment options. With EU approvals in two distinct molecular targets in advanced NSCLC, ROS1 and ALK, XALKORI continues to break new ground and exemplify our commitment to precision drug development and patients."

Pfizer indicated that XALKORI is recognized widely as a first-line normal care for patients with ALK-positive advanced NSCLC. It has been approved in nearly 90 countries. The company pointed out that over 25,000 patients got the treatment with XALKORI throughout the world.

The stock closed Tuesday at $34.88, shedding $0.23 or 0.66 percent.

See more from Benzinga

• Here Are All The Big Biotech Mergers In 2016

• Pfizer Buys Medivation For Billion, Accelerating Its Pathway To Be A Leader In Oncology

• The Least Popular Stocks This 13F Season

© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.